Research Paper Volume 15, Issue 24 pp 15473—15488
Efficacy and safety analysis of a HER2-targeting antibody-drug conjugate combined with immune checkpoint inhibitors in solid tumors: a real-world study
Figure 3. Progression-free survival (PFS) of all patients (A), patients treated with Disitamab Vedotin combined with ICIs and Disitamab Vedotin alone (B), patients with different expression levels of HER2 (C), and patients with urinary cancer and other types of cancer (D).